Elite Journal of Medicine. Volume 1 issue 1(2023), Pp. 17-30
https://epjournals.com/journals/EJM

Hemochromatosis and HIV: Implications for Immune Reconstitution

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Hemochromatosis and HIV are two distinct conditions with overlapping implications for immune function and disease progression. Hemochromatosis, characterized by excessive iron accumulation, and HIV, a chronic viral infection, both impact immune regulation and response. This review explores the implications of hemochromatosis and iron overload for immune reconstitution in the context of HIV infection, with a focus on underlying mechanisms and potential therapeutic interventions. Mechanisms of iron dysregulation in HIV and hemochromatosis are discussed, highlighting the role of hepcidin in mediating the interplay between iron metabolism and immune function. Additionally, the impact of iron overload on antiretroviral therapy (ART) efficacy and toxicity is considered, along with potential therapeutic interventions to optimize immune reconstitution in individuals with HIV and hemochromatosis. Understanding the complex interactions between iron dysregulation, immune function, and ART is crucial for optimizing treatment strategies and improving outcomes in individuals living with HIV and hemochromatosis.

Keywords*: Hemochromatosis, HIV, Immune reconstitution, Iron overload, Antiretroviral therapy, Hepcidin*

Introduction

Hemochromatosis and HIV represent two distinct yet intersecting realms of medical concern, both with profound implications for immune function and disease management. Hemochromatosis, characterized by excessive iron accumulation, and HIV, a chronic viral infection, pose unique challenges to the immune system and overall health. Understanding the complex interplay between these conditions is crucial for optimizing treatment strategies and improving outcomes in affected individuals. HIV infection is characterized by progressive immune dysfunction, leading to

increased susceptibility to opportunistic infections and malignancies. The dysregulation of immune function in HIV results from direct viral effects, chronic inflammation, and depletion of CD4+ T cells, which play a central role in orchestrating immune responses. Antiretroviral therapy (ART) has revolutionized the management of HIV by suppressing viral replication and restoring immune function. However, immune reconstitution may be incomplete in some individuals, particularly those with underlying comorbidities such as hemochromatosis.[1-15]

Hemochromatosis, the most common inherited disorder of iron metabolism, leads to systemic iron overload and predisposes affected individuals to a range of complications, including liver disease, cardiomyopathy, and endocrine abnormalities. Excessive iron accumulation promotes oxidative stress, inflammation, and tissue damage, which may further exacerbate immune dysregulation in individuals with HIV. The coexistence of HIV and hemochromatosis presents unique challenges for immune reconstitution and disease management, necessitating a comprehensive understanding of the underlying mechanisms. The mechanisms underlying iron dysregulation in HIV and hemochromatosis involve complex interactions between chronic inflammation, dysregulated hepcidin expression, and comorbidities associated with both conditions. Hepcidin, a key regulator of iron metabolism, plays a central role in mediating the interplay between iron dysregulation and immune function. Dysregulated hepcidin expression in response to HIV-induced inflammation may contribute to iron sequestration within macrophages and alter iron distribution to tissues and organs. The implications of hemochromatosis and iron overload for immune reconstitution in individuals living with HIV are multifaceted. Excessive iron accumulation may exacerbate immune dysregulation and impair immune reconstitution following initiation of ART. Furthermore, iron overload may impact the efficacy and toxicity of ART, affecting drug metabolism, treatment efficacy, and the risk of drug-induced toxicities. Understanding the complex interactions between iron dysregulation, immune function, and ART is essential for optimizing treatment strategies and improving outcomes in individuals living with HIV and hemochromatosis.[16-50]

Mechanisms of Iron Dysregulation in HIV and Hemochromatosis

Iron dysregulation in individuals living with HIV and hemochromatosis involves complex interactions between chronic inflammation, dysregulated hepcidin expression, and comorbidities associated with both conditions. These mechanisms contribute to systemic iron overload, oxidative stress, and tissue damage, with implications for immune function and disease progression. HIV infection is characterized by chronic inflammation and immune activation, driven by persistent viral replication and immune dysregulation. Pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) stimulate the production of hepcidin, a key regulator of iron metabolism, by hepatocytes. Similarly, chronic inflammation in hemochromatosis contributes to dysregulated hepcidin expression, leading to increased iron absorption and sequestration within macrophages. Hepcidin plays a central role in mediating iron homeostasis by binding to ferroportin, the sole known iron exporter in vertebrates, and inducing its internalization and degradation. Dysregulated hepcidin expression in response to HIV-induced inflammation may contribute to hepcidin deficiency, leading to uncontrolled iron absorption and sequestration. In

hemochromatosis, genetic mutations in the HFE gene disrupt hepcidin regulation, resulting in impaired iron sensing and increased iron absorption.[51-70]

Comorbidities associated with HIV infection, such as viral hepatitis, liver fibrosis, and non-alcoholic fatty liver disease (NAFLD), further exacerbate iron dysregulation by impairing hepatic iron clearance and promoting iron deposition within hepatocytes. Liver damage and fibrosis compromise the regulatory function of hepatocytes in storing and releasing iron, leading to systemic iron overload and oxidative stress. Additionally, comorbidities such as renal dysfunction and chronic kidney disease may impair iron metabolism and exacerbate iron overload in individuals with HIV and hemochromatosis. Dysregulated iron metabolism in HIV and hemochromatosis may lead to aberrant iron redistribution within the body, affecting various organs and tissues. Excessive iron accumulation promotes oxidative stress and tissue damage, contributing to immune dysregulation and disease progression. Iron deposition within macrophages, hepatocytes, and other tissues may further exacerbate inflammation and tissue injury, creating a vicious cycle of iron dysregulation and immune dysfunction. Iron-mediated oxidative stress and mitochondrial dysfunction play a critical role in the pathogenesis of HIV and hemochromatosis. Excessive iron accumulation promotes the generation of reactive oxygen species (ROS) and oxidative damage to cellular components, including mitochondrial DNA, proteins, and lipids. Mitochondrial dysfunction further compromises cellular energy metabolism and exacerbates immune dysregulation, contributing to disease progression in individuals with HIV and hemochromatosis.[71-90]

Implications for Immune Reconstitution

The presence of hemochromatosis and iron overload in individuals living with HIV has significant implications for immune reconstitution, particularly following initiation of antiretroviral therapy (ART). Immune reconstitution refers to the restoration of immune function and CD4+ T cell counts in response to effective ART, which is crucial for controlling viral replication, preventing opportunistic infections, and improving overall health outcomes. However, several factors associated with hemochromatosis and iron overload may impact immune reconstitution in individuals with HIV. Excessive iron accumulation promotes chronic inflammation, oxidative stress, and tissue damage, which may impair immune function and delay immune reconstitution in individuals with HIV. Iron-mediated oxidative stress can damage immune cells, including CD4+ T cells, impairing their function and survival. Furthermore, iron overload may exacerbate HIV-induced immune dysregulation, leading to persistent immune activation and inflammation, which can hinder immune reconstitution despite effective viral suppression. Iron overload has been associated with impaired T cell function and differentiation, which may compromise immune reconstitution in individuals with HIV. CD4+ T cells are critical for orchestrating immune responses and maintaining immune homeostasis. However, iron-mediated oxidative stress and mitochondrial dysfunction may impair T cell proliferation, cytokine production, and effector function, leading to suboptimal immune reconstitution and increased susceptibility to opportunistic infections.[91-100]

Iron dysregulation may contribute to viral persistence and reservoir formation in individuals with HIV, further complicating immune reconstitution efforts. Iron-mediated oxidative stress and mitochondrial dysfunction may promote HIV replication and latency by creating a microenvironment conducive to viral persistence. Additionally, iron overload may impair the function of immune cells involved in controlling viral replication, such as natural killer cells and cytotoxic T lymphocytes, allowing for ongoing viral replication and persistence despite ART. The presence of hemochromatosis and iron overload may impact the response to ART and the effectiveness of immune reconstitution in individuals with HIV. Iron-mediated alterations in drug metabolism and distribution may affect ART pharmacokinetics and pharmacodynamics, potentially compromising treatment efficacy. Furthermore, iron overload may increase the risk of drug-induced toxicities and adverse effects, which can hinder adherence to ART and undermine immune reconstitution efforts. Targeting iron metabolism pathways represents a potential therapeutic strategy for optimizing immune reconstitution in individuals with HIV and hemochromatosis. Modulating hepcidin activity, for example, may help mitigate the adverse effects of iron overload on immune function and treatment outcomes. Additionally, further research is needed to identify novel therapeutic targets for managing iron dysregulation and optimizing immune reconstitution in this population.[101-104]

Effects on Antiretroviral Therapy

The presence of hemochromatosis and iron overload in individuals living with HIV has significant implications for antiretroviral therapy (ART), affecting drug metabolism, treatment efficacy, and toxicity. Understanding the complex interactions between iron dysregulation and ART is essential for optimizing treatment strategies and improving outcomes in affected individuals. Iron is known to interact with drug absorption, distribution, metabolism, and excretion processes, potentially altering the pharmacokinetics of ART agents. Several antiretroviral drugs, including protease inhibitors and non-nucleoside reverse transcriptase inhibitors, are substrates for cytochrome P450 enzymes and drug transporters that may be influenced by iron status. Iron overload may therefore affect the metabolism of ART drugs, leading to altered plasma concentrations and potential changes in treatment efficacy. Iron dysregulation may impact the efficacy of ART in individuals with HIV and hemochromatosis. Excessive iron accumulation has been associated with immune dysregulation and impaired immune reconstitution, which can compromise the effectiveness of ART in suppressing viral replication and restoring immune function. Furthermore, iron-mediated oxidative stress and mitochondrial dysfunction may exacerbate HIV-induced immune dysfunction, further undermining treatment efficacy.[105-107]

Iron overload may increase the risk of drug-induced toxicities and adverse effects in individuals receiving ART. Some antiretroviral agents, such as nucleoside reverse transcriptase inhibitors (NRTIs), are associated with mitochondrial toxicity and hepatotoxicity, which may be exacerbated by iron-mediated oxidative stress and hepatic injury. Additionally, iron overload may predispose individuals to drug-induced liver injury and other adverse effects, necessitating close monitoring and dose adjustments. Iron chelators, used to treat iron overload, may interact with ART drugs, potentially affecting their absorption, distribution, metabolism, and excretion. Similarly, ART drugs may influence the pharmacokinetics of iron chelators, leading to altered drug concentrations

and potential adverse effects. Careful monitoring and dose adjustments may be necessary when co-administering iron chelators and ART drugs to minimize the risk of drug interactions and optimize treatment outcomes. Optimizing ART regimens in the context of iron overload requires careful consideration of drug interactions, treatment efficacy, and potential toxicities. Individualized treatment approaches may be necessary to account for variations in iron status, comorbidities, and treatment responses. Clinicians should monitor iron status and hepatic function regularly and adjust ART regimens accordingly to minimize the risk of adverse effects and optimize treatment outcomes in individuals with HIV and hemochromatosis.[100-103]

Potential Therapeutic Interventions

Addressing iron dysregulation in individuals living with HIV and hemochromatosis requires a multifaceted approach aimed at optimizing immune function, minimizing disease progression, and reducing treatment-related complications. Iron chelators, such as deferoxamine, deferiprone, and deferasirox, are commonly used to treat iron overload by binding to excess iron and facilitating its excretion from the body. Iron chelation therapy has been shown to reduce iron burden, improve liver function, and ameliorate iron-related complications in individuals with hemochromatosis and other iron overload disorders. However, the safety and efficacy of iron chelators in individuals living with HIV require further investigation, particularly regarding potential drug interactions with antiretroviral drugs and their impact on treatment outcomes. Hepcidin, a key regulator of iron metabolism, plays a central role in mediating the interplay between iron dysregulation and immune function. Modulating hepcidin activity represents a potential therapeutic strategy for managing iron overload in individuals with HIV and hemochromatosis. Hepcidin agonists or antagonists may help restore iron homeostasis and mitigate the adverse effects of iron overload on immune function and disease progression. Further research is needed to identify novel therapeutic agents targeting hepcidin and evaluate their efficacy and safety in clinical settings.[95-100]

Optimizing ART regimens in the context of iron overload requires careful consideration of drug interactions, treatment efficacy, and potential toxicities. Individualized treatment approaches may be necessary to account for variations in iron status, comorbidities, and treatment responses. Clinicians should monitor iron status and hepatic function regularly and adjust ART regimens accordingly to minimize the risk of adverse effects and optimize treatment outcomes in individuals with HIV and hemochromatosis. Lifestyle modifications, such as dietary changes and blood donation, may help reduce iron burden and mitigate the adverse effects of iron overload in individuals with HIV and hemochromatosis. Adopting a diet low in iron-rich foods and high in antioxidants may help reduce iron absorption and oxidative stress. Additionally, regular blood donation can effectively reduce iron levels and prevent iron-related complications in individuals with hemochromatosis. Managing comorbidities associated with HIV and hemochromatosis, such as viral hepatitis, liver fibrosis, and non-alcoholic fatty liver disease (NAFLD), is essential for optimizing treatment outcomes and reducing disease progression. Comprehensive management strategies may include antiviral therapy for viral hepatitis, lifestyle modifications, and pharmacological interventions targeting liver fibrosis and NAFLD.[81-110]

Conclusion

Hemochromatosis and HIV represent two distinct yet intersecting realms of medical concern, each with profound implications for immune function, disease progression, and treatment outcomes. The complex interplay between iron dysregulation and HIV infection poses unique challenges for individuals living with both conditions, necessitating a comprehensive understanding of the underlying mechanisms and potential therapeutic interventions. Iron dysregulation in individuals with HIV and hemochromatosis involves complex interactions between chronic inflammation, dysregulated hepcidin expression, and comorbidities associated with both conditions. Excessive iron accumulation promotes oxidative stress, tissue damage, and immune dysregulation, which may impair immune reconstitution, exacerbate HIV pathogenesis, and compromise treatment outcomes.

References

1. Devi P, Khan A, Chattopadhyay P, Mehta P, Sahni S, Sharma S, Pandey R. Co-infections as modulators of disease outcome: minor players or major players? Frontiers in microbiology. 2021; 12:664386.
2. Zanella I, Focà E, Degli-Antoni M, Castelli F, Quiros-Roldan E. An HIV elite controller patient carrying the homozygous H63D variant in the homeostatic iron regulator gene: A case report. Medicine. 2021;100(45): e27732.
3. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019 ;11(3):200.
4. Paparizos V, Kourkounti S. HIV Infection and AIDS: The Present Status of Antiretroviral Therapy. InEuropean Handbook of Dermatological Treatments 2023; 429-442. Cham: Springer International Publishing.
5. Cai CW, Sereti I. Residual immune dysfunction under antiretroviral therapy. InSeminars in immunology 2021; 51: 101471. Academic Press.
6. Sundermann EE, Erlandson KM, Pope CN, Rubtsova A, Montoya J, Moore AA, Marzolini C, O'Brien KK, Pahwa S, Payne BA, Rubin LH. Current challenges and solutions in research and clinical care of older persons living with HIV: Findings presented at the 9th international workshop on HIV and aging. AIDS research and human retroviruses. 2019;35(11-12):985-98.
7. Ahmed D, Roy D, Cassol E. Examining relationships between metabolism and persistent inflammation in HIV patients on antiretroviral therapy. Mediators of inflammation. 2018.
8. Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. Aids. 2008;22: S7-12.
9. Obeagu EI. Comparative Study of Serum Iron and Hemoglobin Levels of Cord Blood of Normal Neonates and that of Maternal Blood in Federal Medical Centre Owerri. Journal of Clinical and Laboratory Research. 2021;4(1):2768-0487.
10. Obeagu EI, Aneke J, Okafor CN, Essein UC, Ochei KC, Obeagu GU. Assessment of Serum Iron Status of Malnourished Infants in Umuahia, Abia State, Nigeria. Sch J App Med Sci. 2016; 4:4384-7.

11. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471.
12. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
13. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
14. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
15. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
16. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
17. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
18. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
19. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
20. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
21. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
22. Obeagu EI, Oshim IO, Ochei KC, Obeagu GU. Iron and blood donation: A Review. Int. J. Curr. Res. Med. Sci. 2016;2(10):16-48.
23. Obeagu EI, Obeagu GU, Emeonye OP, Jakheng SP. An Upadte on Interleukin 6 And Iron Status of Volleyball Players. Madonna University journal of Medicine and Health Sciences. 2022;2(2):41-74.
24. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.

25. Obeagu EI, Anierobi CC, Eze GC, Chukwueze CM, Makonyonga RD, Amadi NM, Hassan R. Evaluation of Plasma Levels of Interleukin 6 and Iron Status of Volleyball Players in a Nigerian University. Journal of Advances in Medical and Pharmaceutical Sciences. 2022;24(6):18-23.
26. Obeagu EI, Obeagu GU, Guevara ME, Okafor CJ, Bot YS, Eze GC, Amadi NM, Jakheng EW, Uwakwe OS. Evaluation of Plasma Levels of Interleukin 6 and Iron of Volleyball Players Based on Heights and Weight of a Nigerian University Students. Asian Journal of Medicine and Health. 2022;20(10):147-152.
27. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
29. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
30. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
31. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
32. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
33. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
34. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.

35. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
36. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
37. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
38. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
39. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
40. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
41. Obeagu E, Felix CE, MTB O, Chikodili UM, Nchekwubedi C1S, Chinedum OK. Studies on some cytokines, CD4, iron status, hepcidin and some haematological parameters in pulmonary tuberculosis patients based on duration of treatment in Southeast, Nigeria. African Journal of Biological Sciences. 2021;3(1):146-156.
42. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021;33(27A):36-43.
43. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
44. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-18.
45. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138.
46. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.

47. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
48. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
49. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
50. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
51. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
52. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
53. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
54. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
55. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies

Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.

56. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
57. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
58. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
59. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
60. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
61. Obeagu EI, Nwazu ME, Obeagu GU. Evaluation of plasma levels of interleukin 6 and iron status based on sleeping patterns of students in a Nigerian University. Int. J. Curr. Res. Med. Sci. 2022;8(9):1-6.
62. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences. 2022;2(1):218-234.
63. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
64. Obeagu EI, Babar Q. Recent advances in understanding of Haemochromatosis: A burning issue of life. Int. J. Curr. Res. Med. Sci. 2021;7(7):23-28.
65. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. Int. J. Curr. Res. Med. Sci. 2018;4(10):42-48.
66. Edward Henry SI, Obeagu EI. Assessment of the Serum Iron Status of Preeclampsia Subjects in Aba, Abia State. Elite Journal of Haematology. 2024;2(1):10-18.
67. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
68. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI:

10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.

69. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
70. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
71. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
72. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
73. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
74. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
75. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
76. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
77. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
78. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
79. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.

80. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
81. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
82. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
83. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
84. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
85. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
86. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
87. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
88. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
89. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
90. Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. Elite Journal of Health Science, 2023; 1(1):1-11
91. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Shielding Infants from HIV Transmission. Elite Journal of Health Science, 2023; 1(1):12-22
92. Obeagu EI, Obeagu GU. Protecting Generations: Early Infant Diagnosis's Role in Preventing HIV Spread. Elite Journal of Public Health, 2023; 1 (1): 1-11
93. Obeagu EI, Obeagu GU. Securing Health: The Role of Early Infant Diagnosis in Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 12-22
94. Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 23-33

95. Obeagu EI, Obeagu GU. From Classroom to Home: Strengthening the Continuum of Sickle Cell Disease Knowledge. Elite Journal of Health Science, 2023; 1(1):23-29
96. Obeagu EI, Obeagu GU. Incorporating Sickle Cell Disease Curriculum in Schools: An Effective Approach. Elite Journal of Health Science, 2023; 1(1):30-36
97. Obeagu EI, Obeagu GU. Community Leaders as Educators: Mobilizing for Sickle Cell Disease Reduction. Elite Journal of Health Science, 2023; 1(1):37-43
98. Obeagu EI, Obeagu GU. Peer-to-Peer Learning Networks: Sickle Cell Disease Education Among Adolescents. Elite Journal of Public Health, 2023; 1 (1): 34-41
99. Obeagu EI, Obeagu GU. From Awareness to Action: Encouraging Adolescent Engagement in Sickle Cell Disease Prevention. Elite Journal of Public Health, 2023; 1 (1): 42-50
100. Obeagu EI, Obeagu GU. The Vital Role of Antioxidants in Enhancing Fertility and Pregnancy Success: A Review. Elite Journal of Nursing and Health Science, 2023; 1(1):1-12
101. Obeagu EI, Obeagu GU. Harnessing the Power of Antioxidant-Rich Diet for Preconception Health: A Review. Elite Journal of Health Science, 2023; 1(1):1-13
102. Obeagu EI. Unraveling Diagnostic Challenges of Aplastic Anemia in the Context of HIV: A Review. Elite Journal of Nursing and Health Science, 2023; 1(1):13-23
103. Obeagu EI. **I**mmunological Insights into Aplastic Anemia within the Context of HIV: Unraveling the Complex Interplay. Elite Journal of Health Science, 2023; 1(1):14-24
104. Obeagu EI. Treatment Strategies for Aplastic Anemia in HIV: Current Approaches and Future Directions. Elite Journal of Laboratory Medicine, 2023; 1(1): 1-12
105. Hackl L, Itzkowitz L, Koso-Thomas M, Moorthy D, Owino V, Pachón H, Stoffel N, Zimmerman M, Raiten D, Loechl C, Datta-Mitra A. Approaches to Address the Anemia Challenge. The Journal of Nutrition. 2023;153(Suppl 1).
106. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2012;1823(9):1434-1443.
107. Ibrahim SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, Wolf JL, Sundaram SS. Liver diseases in the perinatal period: interactions between mother and infant. Hepatology. 2020;71(4):1474
108. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV, 2023; 1(1): 15-28
109. Obeagu EI. Hemochromatosis and HIV: Two Conditions, One Challenge. Elite Journal of Laboratory Medicine, 2023; 1(1): 13-27
110. Obeagu EI. Iron Overload in HIV: Implications for Antiretroviral Therapy. Elite Journal of Health Science, 2023; 1(1):25-37